<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We report the first clinicopathological series of longitudinal FDG-PET scans in post-mortem (PM) verified cognitively <z:mpath ids='MPATH_458'>normal</z:mpath> elderly (NL) followed to the <z:hpo ids='HP_0003674'>onset</z:hpo> of Alzheimer's-type <z:hpo ids='HP_0000726'>dementia</z:hpo> (DAT), and in patients with mild DAT with progressive <z:e sem="disease" ids="C0854193" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive deterioration</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Four NL subjects and three patients with mild DAT received longitudinal clinical, neuropsychological and dynamic FDG-PET examinations with arterial input functions </plain></SENT>
<SENT sid="2" pm="."><plain>NL subjects were followed for 13 +/- 5 years, received FDG-PET examinations over 7 +/- 2 years, and autopsy 6 +/- 3 years after the last FDG-PET </plain></SENT>
<SENT sid="3" pm="."><plain>Two NL declined to mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI), and two developed probable DAT before <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>DAT patients were followed for 9 +/- 3 years, received FDG-PET examinations over 3 +/- 2 years, and autopsy 7 +/- 1 years after the last FDG-PET </plain></SENT>
<SENT sid="5" pm="."><plain>Two DAT patients progressed to moderate-to-severe <z:hpo ids='HP_0000726'>dementia</z:hpo> and one developed vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The two NL subjects who declined to DAT received a PM diagnosis of definite AD </plain></SENT>
<SENT sid="7" pm="."><plain>Their FDG-PET scans indicated a progression of deficits in the cerebral metabolic rate for <z:chebi fb="105" ids="17234">glucose</z:chebi> (CMRglc) from the hippocampus to the parietotemporal and posterior cingulate cortices </plain></SENT>
<SENT sid="8" pm="."><plain>One DAT patient showed AD with <z:e sem="disease" ids="C0752347" disease_type="Disease or Syndrome" abbrv="DLB">diffuse Lewy body disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e>) at PM, and her last in vivo PET was indicative of possible <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e> for the presence of occipital as well as parietotemporal hypometabolism </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Progressive CMRglc reductions on FDG-PET occur years in advance of clinical DAT symptoms in patients with pathologically verified disease </plain></SENT>
<SENT sid="10" pm="."><plain>The FDG-PET profiles in life were consistent with the PM diagnosis </plain></SENT>
</text></document>